Home HighLife SAS

HighLife SAS

HighLife Closes €12.3 Million Financing Round Led by Sofinnova Partners

HighLife SAS, an early-stage medtech company focused on the development of a unique trans-catheter mitral valve replacement system to treat patients suffering from mitral regurgitation, announced today the closing of a €12.3 million investment round led by Sofinnova Partners which becomes the main investor in the company. HighLife had previously secured financing from LivaNova PLC, which also participated in this financing round along with Georg Börtlein, the CEO and founder of HighLife.